SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

STMicroelectronics NV is a global semiconductor company, which engages in the business of designing, developing, manufacturing, and marketing products used in a wide variety of applications for automotive, industrial, personal electronics and communications equipment, computers, and peripherals. It operates through the following segments: Automotive and Discrete Group (ADG), Analog, MEMS, and Sensors Group (AMS), Microcontrollers and Digital ICs Group (MDG), and Others. The ADG segment includes dedicated automotive integrated circuits and discrete and power transistor products. The AMS segment offers analog, smart power, MEMS sensors and actuators, and optical sensing solutions. The MDG segment focuses on general-purpose microcontrollers and microprocessors, connected security products, memories, and RF and communications products. The Others segment is involved in sales assembly services and other revenues. The company was founded in June 1987 and is headquartered in Plan-Les-Ouates, Switzerland.

ST Microelectronics - New York Shares

STMicroelectronics NV

STMicroelectronics ($STM) is trending due to multiple positive news releases, including advancements in image sensors, power solutions for AI factories, and partnerships for decarbonization and interior sensing technology. Bullish sentiment is fueled by strong earnings reports and analyst upgrades, with the community actively discussing its potential for growth in the chip market. However, some investors express concern over unsold inventory and a recent price drop despite the positive news, with potential alternative chip suppliers, like $VWAGY, being explored.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending amidst mixed sentiment as investors approach the upcoming earnings report, with analysts projecting flat growth and margin pressure. Community discussions include potential options plays, concerns about the stock's performance relative to peers, and debate around the impact of buybacks and strategic initiatives. Articles discussing Jim Cramer's views on the company, potential transaction revenues, and beaten-down stocks are circulating.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing ($RGTI) is trending amid mixed sentiment and high volatility, driven by discussions around government funding, insider selling, and technical analysis patterns. The community is debating the company's valuation, future prospects, and potential competition from larger tech companies like IBM and Google. Bears point to weak revenue and director selling, while bulls highlight potential breakthroughs and government interest.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

CockCardano ($COCK) is trending due to its unique meme-based appeal and real-world asset backing through Cocky Wings food trucks, driving community engagement and buybacks. Discussions revolve around upcoming Cocky Wings events, the partnership with $SNEK energy drinks, and the opportunity to earn passive income through staking in the $COCK Arena. The community emphasizes the project's long-term vision, active development, and the potential for significant growth within the Cardano ecosystem.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is trending as investors discuss its sideways trading pattern and potential for a significant breakout, with some highlighting the possibility of a short squeeze due to a low float. Community members are also analyzing recent news, including Thailand's AI investments and potential US market expansion, while awaiting upcoming earnings and contract details. Technical analysis suggests accumulation, but concerns about market manipulation and skepticism regarding company communication persist.

Volatility Shares Trust - Volatility Shares Trust XRP ETF

XRP ETF

XRPI is trending amid discussions about potential benefits from Ripple's partnerships and speculation around asset tokenization. Community members are actively discussing its possible adoption by banks and its potential as a long-term investment within the cryptocurrency space. The possibility of an XRP ETF approval in the US is also a key catalyst driving interest.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending as investors debate whether recent acquisitions will drive future growth, with some expressing concern over dilution and management's strategy. Bullish sentiment centers on the potential for a short squeeze and upcoming earnings, while bears cite historical underperformance and market manipulation. Community members are closely watching for news on key catalysts, including CMS rule updates and real-world data.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

BETR is trending due to excitement around its AI-driven mortgage platform, with community members discussing its potential to disrupt the lending industry. Investors are analyzing recent partnerships and revenue forecasts, while also weighing potential risks like share dilution. Bullish sentiment is fueled by comparisons to high-growth tech companies and anticipation of future rate cuts.

HCM II Acquisition Corp. operates as a blank check company. It was formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 4, 2024 and is headquartered in Stamford, CT.

HCM II Acquisition Corp - Ordinary Shares - Class A

HCM II Acquisition Corp.

HCM II Acquisition Corp. ($HOND) is trending as the merger with Terrestrial Energy approaches, anticipated to finalize around October 28th, with the new ticker $IMSR. The community is weighing the potential for a post-merger drop, typical of SPACs, against the long-term prospects of Terrestrial Energy's advanced nuclear technology, particularly in comparison to sector peer $OKLO. Many believe the new ticker and growing interest in nuclear energy could drive the stock price higher, citing its potential in edge energy markets and backing from government programs.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending due to discussions around its recent FDA approval for Revuforj, a leukemia drug, and its competitive positioning against KURA. The community is weighing the drug's efficacy against safety concerns highlighted by a black box warning, while some speculate about a potential buyout before 2027. Bullish investors suggest this pullback is a buying opportunity, anticipating positive earnings and future analyst upgrades.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Ardelyx Inc. (ARDX) jumped 16% higher on Tuesday morning after multiple brokerages upped their price targets on the stock following an upbeat second-quarter earnings report and management changes.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARDX">ARDX</a> trended in the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘high’ levels. According to Stocktwits data, retail chatter around ARDX jumped 1738% over the past 24 hours, as of Tuesday morning.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_05_at_10_56_25_AM_png_178eba0feb.webp" alt="ARDX's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 5, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>ARDX's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 5, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user heaped praises on the management.<stembedurl>https://stocktwits.com/hpf6637/message/623772356</stembedurl>Another user expressed hopes for further price target increases into the high teens.<stembedurl>https://stocktwits.com/Paul_Volcker/message/623769111</stembedurl>Ardelyx on Monday announced changes to its executive leadership team, including the appointment of Edward Conner as Chief Medical Officer and the exit of CFO Justin Renz. The appointments came on the heels of the company reporting $97.7 million in total revenue, reflecting 33% growth year-over-year, and above an analyst estimate of $81.08 million.Ibsrela, the company’s prescription medicine used in adults to treat irritable bowel syndrome with constipation, generated its highest-ever net sales revenue of $65 million in the quarter. Meanwhile, Xphozah, a prescription medicine used to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy, brought in $25 million in the quarter.The company also raised its Ibsrela net sales revenue expectations to $250 million to $260 million for the full year 2025. Net loss per share came in at $0.08, compared to a loss of $0.07 per share reported in the corresponding quarter of 2024, but below a loss per share of $0.14 expected by analysts.Multiple analysts subsequently hiked their price target on the stock on Tuesday morning. Wedbush raised its price target on Ardelyx to $14 from $13 and kept an ‘Outperform’ rating on the shares. The firm noted that Ardelyx posted a solid performance in Q2, driven by Ibsrela strength.Raymond James, meanwhile, raised the firm's price target on Ardelyx to $12 from $11 and kept an ‘Outperform’ rating on the shares. ARDX stock is up by 1% this year but down by about 12% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-shareholders-reportedly-sue-ev-giant-ceo-elon-musk-over-robotaxi-claims/chrLMCtRd21">Tesla Shareholders Reportedly Sue EV Giant, CEO Elon Musk Over Robotaxi Claims: Retail’s In Wait-And-Watch Mode</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming

Wedbush raised its price target on Ardelyx to $14 from $13 and kept an ‘Outperform’ rating on the shares.

Equity

Wedbush raised its price target on Ardelyx to $14 from $13 and kept an ‘Outperform’ rating on the shares.


Ardelyx (ARDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Ardelyx (ARDX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of +38.46% and +15.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shares of Ardelyx, Inc. (ARDX) traded 22% lower on Friday afternoon after Citi lowered its price target on the stock following its recent first-quarter earnings report.Citi reduced its price target on Ardelyx to $10 from $11 while keeping a ‘Buy’ rating. The new price target, however, represents an 83% upside to the stock’s closing price on Thursday.Raymond James also downgraded Ardelyx to ‘Outperform’ from ‘Strong Buy’, and slashed its price target to $11 from $13.The firm said that recent net sales weakness has created added uncertainty regarding the long-term growth of the Ibsrela and Xphozah franchises.Despite the downgrade, Raymond James remains bullish on Ardelyx, citing its strong execution track record.Ardelyx <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-reports-first-quarter-2025-financial-results-and">reported</a> Q1 total revenue of $74.1 million on Thursday, marking &nbsp;61% growth year-over-year and reflecting increased net product sales and licensing revenue. However, as per Finchat data, this was below an analyst estimate of $79.44 million.U.S. net product sales revenue of Ibsrela, the company’s prescription medication for treating Irritable Bowel Syndrome with Constipation, was $44.4 million, compared to $28.4 million during the same period of 2024.The U.S. net product sales revenue of Xphozah, used as an add-on therapy to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis, was $23.4 million, compared to $15.2 million during the same period in 2024.Net loss per share for the quarter was $0.17, compared to a loss of $0.11 per share in the same quarter of 2024, and broader than an estimated loss of $0.07.On Stocktwits, retail sentiment around ARDX remained in the ‘extremely bullish’ territory over the past 24 hours while message volume rose to ‘extremely high’ from ‘high’.<figure class="image"><img style="aspect-ratio:626/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_02_at_1_56_59_PM_png_99a9fe03a2.webp" alt="ARDX's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 2, 2025 | Source: Stocktwits" width="626" height="59"><figcaption>ARDX's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 2, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> is down by over 17% this year and nearly 38% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/volkswagen-core-brand-group-operating-profit-drops-q1/chLUkWFRb0z">Volkswagen Core Brand Group Operating Profit Drops In Q1: But Retail’s Not Rattled</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Ardelyx Stock Gets Multiple Price Target Cuts After Disappointing Q1 Earnings: But Retail’s Optimistic

Raymond James said that recent net sales weakness has created added uncertainty regarding the long-term growth of the Ibsrela and Xphozah franchises. 

Shares of biopharma company Ardelyx, Inc. (ARDX) edged up about 0.5% in after-hours trading on Thursday after closing lower during the regular session as investors processed its quarterly earnings and drug sales projections.Ardelyx swung to a fourth-quarter (Q4) net income of $0.02 per diluted share from a loss of $0.12 a year earlier, surpassing analyst expectations of breakeven.&nbsp;Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.Total revenue for the year ended Dec. 31, 2024, was $333.6 million, compared to $124.5 million a year earlier.Ibsrela, its treatment for irritable bowel syndrome with constipation, generated $53.8 million in Q4 net product sales revenue, reflecting about 32% growth from Q3.&nbsp;Full-year 2024 sales reached $158.3 million, and the company expects U.S. net product sales for 2025 to range between $240 million and $250 million.&nbsp;Ardelyx projects Ibsrela to achieve over 10% market share at peak and exceed $1 billion in annual U.S. revenue before its patent expires in 2029.Xphozah, used to manage serum phosphorus levels in adults with chronic kidney disease on dialysis, recorded $57.2 million in Q4 net product sales.In 2024, Xphozah's first full year of commercialization saw U.S. sales hit $160.9 million. The company estimates that peak annual U.S. sales will reach $750 million before its patent expires.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ARDX_sentiment_and_message_volume_Feb_20_c5531a04cb.png" alt="ARDX sentiment and message volume Feb 20.png">On Stocktwits, sentiment for ARDX surged deeper into the 'extremely bullish' zone, with message volume spiking 240% in 24 hours.&nbsp;One user highlighted IBSRELA's trajectory toward blockbuster drug status, while another reinforced faith in the company's fundamentals.<stembedurl>https://stocktwits.com/Food4Thought/message/605066169</stembedurl><stembedurl>https://stocktwits.com/Newtothis321/message/604963175</stembedurl>Ardelyx ended 2024 with $250.1 million in cash, cash equivalents, and short-term investments, up from $184.3 million a year earlier.&nbsp;The stock has gained over 13% year-to-date, though short interest has increased from 10% at the start of 2025 to about 11.2% last week, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism

Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.

Ardelyx Beats Q3 Sales Estimates, Shares Climb

Ardelyx reported its third-quarter results after Thursday's closing bell. Here's a look at the details from the report:
read more...

Ardelyx's Earnings Outlook

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardelyx, Inc. (Ardelyx or the Company) (NASDAQ: ARDX) and reminds investors of the October 15...

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

ARDX
Ardelyx Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARDX News

ARDXArdelyx Inc